RenovoRx, Inc.
For the period ended Dec 31, 2024. Filed Apr 1, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 1, 2025
RNXT$1.18+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
RENOVORX, INC.
EXHIBIT INDEX
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit No. | Exhibit Description | Form | File No. | Exhibit | Filing Date |
| 3.1 | Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc. | 8-K | 001-40738 | 3.1 | August 31, 2021 |
| 3.2 | Amended and Restated Bylaws of RenovoRx, Inc. | 8-K | 001-40738 | 3.1 | September 11, 2023 |
| 4.1 | Form of Private Common Stock Warrant (related to the 2020 Convertible Notes and 2021 Convertible Notes) | 10-Q | 001-40738 | 4.1 | November 15, 2021 |
| 4.2 | Form of Underwriter’s Warrant | S-1 | 333-258071 | 4.1 | August 25, 2021 |
| 4.3 | Form of Warrant Agent Agreement (including the terms of the Warrants) | S-1 | 333-258071 | 4.2 | August 25, 2021 |
| 4.4 | Specimen Stock Certificate evidencing the Shares of Common Stock | S-1 | 333-258071 | 4.4 | August 25, 2021 |
| 4.5 | Form of Warrant Certificate | S-1 | 333-258071 | 4.5 | August 25, 2021 |
| 4.6 | Form of Pre-Funded Common Stock Purchase Warrant | 8-K | 001-40738 | 4.1 | April 3, 2023 |
| 4.7 | Form of Common Stock Purchase Warrant | 8-K | 001-40738 | 4.2 | April 3, 2023 |
| 4.8 | Form of Warrant to Purchase Common Stock Issued in January 2024 Private Placement | 8-K | 001-40738 | 10.3 | January 29, 2024 |
| 4.9 | Form of Placement Agent Warrant Issued in January 2024 Private Placement | 8-K | 001-40738 | 10.5 | January 29, 2024 |
| 4.10 | Form of Pre-Funded Common Stock Purchase Warrant issued in April 2024 Private Placement | 8-K | 001-40738 | 10.2 | April 15, 2024 |
| 4.11 | Form of Series A Warrant to Purchase Common Stock issued in April 2024 Private Placement | 8-K | 001-40738 | 10.3 | April 15, 2024 |
| 4.12 | Form of Series B Warrant to Purchase Common Stock issued in April 2024 Private Placement | 8-K | 001-40738 | 10.4 | April 15, 2024 |
| 4.13 | Form of Placement Agent Warrant to Purchase Common Stock issued in April 2024 Private Placement | 8-K | 001-40738 | 10.5 | April 15, 2024 |
| 4.14 | Common Stock Purchase Warrant Issued to Medical Murray, Inc., dated September 25, 2024 | 10-Q | 001-40738 | 4.14 | November 13, 2024 |
| 4.15 | Form of Underwriter Warrant issued in February 2025 Public Offering | 8-K | 001-40738 | 4.1 | February 10, 2025 |
| 4.16 | Description of Securities | 10-K | 001-40738 | 4.6 | March 30, 2022 |
| 10.1 | Amended and Restated Investor Rights Agreement, dated as of April 18, 2018 | 10-Q | 001-40738 | 10.1 | November 15, 2021 |
| 10.2† | Amended and Restated 2021 Omnibus Equity Incentive Plan and Forms of Stock Option Grant Notice and Option Agreement | 10-K | 001-40738 | 10.2 | March 30, 2022 |
| 10.3† | Amended and Restated Outside Director Compensation Policy | 10-K | 001-40738 | 10.3 | April 1, 2024 |
| 10.4† | Confirmatory Offer Letter, by and between RenovoRx, Inc. and Shaun Bagai, dated November 11, 2021 | 10-Q | 001-40738 | 10.4 | November 15, 2021 |
| 10.5† | Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 1, 2018 | 10-Q | 001-40738 | 10.5 | November 15, 2021 |
| 10.6† | Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated November 11, 2021 | 10-Q | 001-40738 | 10.6 | November 15, 2021 |
| 10.7† | Amendment to Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 25, 2022 | 10-K | 001-40738 | 10.7 | March 30, 2022 |
| 10.8† | Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Shaun Bagai, effective as of November 11, 2021 | 10-Q | 001-40738 | 10.7 | November 15, 2021 |
| 10.9† | Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., effective as of November 11, 2021 | 10-Q | 001-40738 | 10.8 | November 15, 2021 |
| 10.10† | Key Service Provider Incentive Compensation Plan | 10-Q | 001-40738 | 10.9 | November 15, 2021 |
| 10.11† | Form of Indemnification Agreement | S-1 | 333-258071 | 10.7 | August 25, 2021 |
| 10.12+ | Master Supply Agreement, by and between Medical Murray, Inc. and RenovoRx, Inc., dated October 28, 2019 | S-1 | 333-258071 | 10.11 | August 25, 2021 |
| 10.13† | Consulting Agreement by and between RenovoRx, Inc. and Danforth Advisors, LLC, dated April 25, 2022 | 8-K | 001-40738 | 10.1 | July 19, 2022 |
| 10.14† | Offer Letter between RenovoRx, Inc. and Angela Gill Nelms, dated August 15, 2022 | 8-K | 001-40738 | 10.1 | September 19, 2022 |
| 10.15† | Change in Control and Severance Agreement by and between RenovoRx, Inc. and Angela Gill Nelms, dated August 17, 2022 | 8-K | 001-40738 | 10.2 | September 19, 2022 |
| 10.16† | Form of Placement Agency Agreement by and between RenovoRx, Inc. and Roth Capital Partners, LLC, dated March 30, 2023 | 8-K | 001-40738 | 10.1 | April 3, 2023 |
| 10.17† | Form of Securities Purchase Agreement | 8-K | 001-40738 | 10.2 | April 3, 2023 |
| 10.18 | Subscription Agreement, by and between RenovoRx, Inc. and the investors thereto | 8-K | 001-40738 | 10.1 | January 29, 2024 |
| 10.19 | Offering Extension, dated January 12, 2024 | 8-K | 001-40738 | 10.2 | January 29, 2024 |
| 10.20 | Placement Agent Agreement, by and between RenovoRx, Inc. and Paulson Investment Company, LLC, dated November 14, 2023 | 8-K | 001-40738 | 10.4 | January 29, 2024 |
| 10.21 | Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Ronald B. Kocak | 8-K | 001-40738 | 10.1 | February 9, 2024 |
| 10.22 | Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Leesa Gentry | 8-K | 001-40738 | 10.1 | March 14, 2024 |
| 10.23 | Form of Subscription Agreement (April 2024 Private Placement) | 8-K | 001-40738 | 10.1 | April 15, 2024 |
| 10.24† | Change in Control and Severance Agreement, by and between RenovoRx, Inc. and Ron Kocak, effective as of June 6, 2024 | 8-K | 001-40738 | 10.1 | June 7, 2024 |
| 16.1 | Letter from Baker Tilly US, LLP, dated May 3, 2024 | 8-K | 001-40738 | 16.1 | May 3, 2024 |
| 19.1 | Insider Trading Policy | 10-K | 001-40738 | 19.1 | April 1, 2024 |
| 23.1 | Consent of Baker Tilly US, LLP | Filed herewith | |||
| 23.2 | Consent of Frank, Rimerman + Co. LLP | Filed herewith | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a). | Filed herewith | |||
| 31.2 | Certification of Principal Accounting Officer Pursuant to Rule 13a-14(a)/15d-14(a). | Filed herewith | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350. | Furnished herewith | |||
| 32.2* | Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350. | Furnished herewith | |||
| 97.1 | Policy Related to Recovery of Erroneously Awarded Compensation, adopted September 7, 2023 | 10-K | 001-40738 | 97.1 | April 1, 2024 |
| 101.INS | Inline XBRL Taxonomy Extension Instance Document (the instance document does not appear on the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). | Filed herewith | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | Filed herewith | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Link base Document | Filed herewith | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith | |||
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | Filed herewith | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in the Interactive Data Files submitted as Exhibit 101). | Filed herewith | |||
† Indicates management contract or compensatory plan or arrangement
- Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(2) of Regulation S-K and RenovoRx, Inc. agrees to furnish supplementally to the Securities and Exchange Commission a copy of any redacted information or omitted schedule and/or exhibit upon request.
- The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.